Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study.
Adult
Aged
Benzoates
/ therapeutic use
Female
Hematologic Diseases
/ complications
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Hydrazines
/ therapeutic use
Italy
Male
Middle Aged
Primary Graft Dysfunction
/ drug therapy
Pyrazoles
/ therapeutic use
Retrospective Studies
Transplantation, Homologous
Treatment Outcome
Young Adult
Cytopenia
Haemopoietic stem cell transplantation eltrombopag
Poor graft function
Thrombopoietin receptor agonist
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
10
11
2020
accepted:
15
04
2021
revised:
14
04
2021
pubmed:
23
4
2021
medline:
10
8
2021
entrez:
22
4
2021
Statut:
ppublish
Résumé
This retrospective study assessed the effectiveness of eltrombopag (EPAG), a thrombopoietin receptor agonist, in the treatment of poor graft function (PGF) following an allogeneic haemopoietic stem cell transplantation (HSCT). Complete response was defined as normalization of blood counts, whereas partial response was defined as transfusion independence. A total of 48 patients with full donor chimerism after HSCT, received EPAG for a median of 120 days (range 10-591). Patients with uni- bi- or tri-lineage cytopenia started treatment at a median of 95 days (range 17-877) after HSCT. The overall response rate was 75%: 24 patients had a complete response and 12 had a partial response. Positive predictors of response were an HLA-matched donor, a CD34
Identifiants
pubmed: 33886103
doi: 10.1007/s12185-021-03153-3
pii: 10.1007/s12185-021-03153-3
doi:
Substances chimiques
Benzoates
0
Hydrazines
0
Pyrazoles
0
eltrombopag
S56D65XJ9G
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
228-234Informations de copyright
© 2021. Japanese Society of Hematology.
Références
Balassa K, Danby R, Rocha V. Haematopoietic stem cell transplants: principles and indications. Br J Hosp Med. 2019;80(1):33–9.
doi: 10.12968/hmed.2019.80.1.33
McSweeney PA, Storb R. Mixed chimerism: preclinical studies and clinical applications. Biol Blood Marrow Transplant. 1999;5(4):192–203.
doi: 10.1053/bbmt.1999.v5.pm10465099
Murphy KM. Chimerism analysis following hematopoietic stem cell transplantation. In: Czader M, editor. Hematological malignancies. Methods in molecular biology (methods and protocols), vol. 999. Totowa: Humana Press; 2013.
Dominietto A, Raiola AM, van Lint MT, Lamparelli T, Gualandi F, Berisso G, et al. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol. 2001;112(1):219–27.
doi: 10.1046/j.1365-2141.2001.02468.x
Lee KH, Lee JH, Choi SJ, Kim S, Seol M, Lee YS, et al. Failure of trilineage blood cell reconstitution after initial neutrophil engraftment in patients undergoing allogeneic hematopoietic cell transplantation - frequency and outcomes. Bone Marrow Transplant. 2004;33(7):729–34.
doi: 10.1038/sj.bmt.1704428
Sun Y-Q, He G-L, Chang Y-J, Lan-Ping Xu, Zhang X-H, Han W, et al. The incidence, risk factors, and outcomes of primary poor graft function after unmanipulatedhaploidentical stem cell transplantation. Ann Hematol. 2015;94:1699–705.
doi: 10.1007/s00277-015-2440-x
Labrador J, López-Corral L, Vazquez L, Sánchez-Guijo F, Guerrero C, Sánchez-Barba M, et al. Incidence and risk factors for life-threatening bleeding after allogeneic stem cell transplant. Br J Haematol. 2015;169(5):719–25.
doi: 10.1111/bjh.13344
Guardiola P, Kuentz M, Garban F, Blaise D, Reiffers J, Attal M, et al. Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation. Br J Haematol. 2000;111(1):292–302.
pubmed: 11091216
Bittencourt H, Rocha V, Filion A, Ionescu I, Herr AL, Garnier F, et al. Granulocyte colony-stimulating factor for poor graft function after allogeneic stem cell transplantation: 3 days of G-CSF identifies long-term responders. Bone Marrow Transplant. 2005;36(5):431–5.
doi: 10.1038/sj.bmt.1705072
Stasia A, Ghiso A, Galaverna F, Raiola AM, Gualandi F, Luchetti S, et al. CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(9):1440–3.
doi: 10.1016/j.bbmt.2014.05.016
Liu X, Wu M, Peng Y, Chen X, Sun J, Huang F, et al. Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study. Cell Transplant. 2014;23(9):1087–98.
doi: 10.3727/096368912X661319
Ghobadi A, Fiala MA, Ramsingh G, Gao F, Abboud CN, Stockerl-Goldstein K, et al. Fresh or cryopreserved CD34(+)-selected mobilized peripheral blood stem and progenitor cells for the treatment of poor graft function after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2017;23(7):1072–7.
doi: 10.1016/j.bbmt.2017.03.019
Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376(16):1540–50.
doi: 10.1056/NEJMoa1613878
Mahat U, Rotz SJ, Hanna R. Use of thrombopoietin receptor agonists in prolonged thrombocytopenia after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020;26(3):e65–73.
doi: 10.1016/j.bbmt.2019.12.003
Rivera D, Bastida JM, Lopez-Corral L, Sanchez-Guijo F, Cabrero M, Martin A, et al. Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2019;54(5):757–61.
doi: 10.1038/s41409-018-0368-1
Fu H, Zhang X, Han T, Mo X, Wang Y, Chen H, et al. Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019;54(8):1310–8.
doi: 10.1038/s41409-019-0435-2
Yuan C, Boyd AM, Nelson J, Patel RD, Varela JC, Goldstein SC, et al. Eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(7):1320–4.
doi: 10.1016/j.bbmt.2019.01.027
Tang C, Chen F, Kong D, Ma Q, Dai H, Yin J, et al. Successful treatment of secondary poor graft function post allogeneic hematopoietic stem cell transplantation with eltrombopag. J HematolOncol. 2018;11(1):103.
Marotta S, Marano L, Ricci P, Cacace F, Frieri C, Simeone L, et al. Eltrombopag for post-transplant cytopenias due to poor graft function. Bone Marrow Transplant. 2019;54(8):1346–53.
doi: 10.1038/s41409-019-0442-3
Raut SS, Shah SA, Sharanangat VV, Shah KM, Patel KA, Anand AS, et al. Safety and efficacy of eltrombopag in post-hematopoietic stem cell transplantation (HSCT) thrombocytopenia. Indian J Hematol Blood Transfus. 2015;31(4):413–5.
doi: 10.1007/s12288-014-0491-0
Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K, Kurosawa S, et al. Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(5):919–24.
doi: 10.1016/j.bbmt.2016.01.018
Narita Y, Uchiyama T, Mizumoto C, Takeoka T, Tomo K, Tsuji M, et al. Successful treatment of post-allogeneic hematopoietic transplant immune thrombocytopenia with eltrombopag. Rinsho Ketsueki. 2018;59(11):2418–22.
pubmed: 30531136
Master S, Dwary A, Mansour R, Mills GM, Koshy N. Use of eltrombopag in improving poor graft function after allogeneic hematopoietic stem cell transplantation. Case Rep Oncol. 2018;11(1):191–5.
doi: 10.1159/000487229
Reid R, Bennett JM, Becker M, Chen Y, Milner L, Phillips GL, et al. Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia. Am J Hematol. 2012;87(7):743–5.
doi: 10.1002/ajh.23225
Fujimi A, Kamihara Y, Hashimoto A, Kanisawa Y, Nakajima C, Hayasaka N, et al. Identification of anti-thrombopoietin receptor antibody in prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation treated successfully with eltrombopag. Int J Hematol. 2015;102(4):471–6.
doi: 10.1007/s12185-015-1806-0
Dyba J, Tinmouth A, Bredeson C, Matthews J, Allan DS. Eltrombopag after allogeneic haematopoietic cell transplantation in a case of poor graft function and systematic review of the literature. Transfus Med. 2016;26(3):202–7.
doi: 10.1111/tme.12300
Li S, Wu R, Wang B, Fu L, Zhu G, Zhou X, et al. Eltrombopag for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation in children. J PediatrHematolOncol. 2019;41(1):38–41.
Marjanska A, Czyzewski K, Debski R, Krenska A, Wysocki M, Styczynski J. The successful sequential use of plerixafor and eltrombopag for hematopoietic cell transplantation in a child with high-risk neuroblastoma. J PediatrHematolOncol. 2020;42(7):e680–2.
Gao F, Zhou X, Shi J, Luo Yi, Tan Y, Huarui Fu, et al. Eltrombopag treatment promotes platelet recovery and reduces platelet transfusion for patients with post-transplantation thrombocytopenia. Ann Hematol. 2020;99(11):2679–87.
doi: 10.1007/s00277-020-04106-2
Clark JR, Scott SD, Jack AL, Lee H, Mason J, Carter GI, et al. Monitoring of chimerism following allogeneic haematopoietic stem cell transplantation (HSCT): technical recommendations for the use of short tandem repeat (STR) based techniques, on behalf of the United Kingdom National External Quality Assessment Service for Leucocyte ImmunophenotypingChimerism Working Group. Br J Haematol. 2015;168(1):26–37.
doi: 10.1111/bjh.13073